Testing dolutegravir dosing in HIV and TB children
Treatments studied
Part of Infections clinical trials.
This study looks at the right way to dose dolutegravir (an HIV medicine) in young children who also have active tuberculosis (TB). Doctors will measure how the medicine moves through the body, especially when standard vs higher-dose rifampicin is used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a child age 4 weeks to under 6 years
- Have HIV infection and be diagnosed with active TB
- Weigh at least 3 kilograms
- Have a parent or legal guardian who can consent
- Recent blood tests must not show serious organ or blood problems (ALT, bilirubin, ANC, platelets, or creatinine)
- No signs of TB meningitis or severe breathing problems right now
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how dolutegravir (an HIV medicine) works in children when taken with weekly rifapentine and isoniazid (medicines to prevent tuberculosis). It may help find the right dose for kids who have HIV and are at risk for TB.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This study tests a daily combination of two medicines, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13 years old. It aims to see if this short treatment is safe and works well for kids, including those living with HIV.
This trial tests a two-drug HIV treatment for people who are new to HIV therapy and also have tuberculosis. It compares the two-drug combination to the standard three-drug regimen, with the goal of making treatment simpler while still being effective.
This trial tests different HIV medicines in children and teenagers to find safer, more effective options. It aims to improve viral suppression and overall health for young people living with HIV.
This study tests if a shorter course of tuberculosis (TB) medicine works as well as the current longer treatment for children. If successful, it means fewer days of medicine and fewer side effects for kids.
Hear when a new Tuberculosis Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.